Stephen P. Lockhart

机构：Pfizer (United States), Pfizer (United Kingdom) · ORCID：0000-0002-0805-2193

发表论文 92 篇 · 总被引 26902 次 · h-index 30

代表论文

• Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2021 · New England Journal of Medicine · 被引 628)
• SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 (2021 · New England Journal of Medicine · 被引 420)
• Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years (2023 · New England Journal of Medicine · 被引 123)
• Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age (2023 · New England Journal of Medicine · 被引 106)
• Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial (2021 · Vaccine · 被引 58)
• CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection (2024 · Clinical Infectious Diseases · 被引 41)